The addition of Avastin, in combination with intravenous 5-Fluorouracil-based chemotherapy, has been shown to increase survival time these patients. Dr. Richard Goldberg, associate director of the Lineberger Comprehensive Cancer Center, UNC, Chapel Hill says, “Attacking blood vessel growth with Avastin is a whole new way of treating cancer. When you combine the attack on blood vessels with an attack on the cancer cell directly using chemotherapy, it's a one-two punch.”
Avastin is the first FDA-approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. Avastin was specifically designed to interrupt this process, impacting the tumor's ability to grow and spread. Serious risks are associated with Avastin therapy. Patients should consult with their healthcare provider regarding the risks and benefits of therapy.
Courtesy: Medialink
The FDA has approved Avastin, the first anti-angiogenesis cancer therapy proven to increase survival time in patients who had not received previous treatment for metastatic colorectal cancer -- the second most common cause of cancer death in the US. 
